Going forward, ISS will recommend against all board nominees each year as long as the company maintains a long-term poison pill (duration of more than 1 year) that has not been approved by shareholders. ISS will no longer consider a board's undertaking to put a long-term pill to a vote of shareholders the following year as a "mitigating factor" when assessing the pill. Previously grandfathered boards of companies with 10-year pills from 2009 will no longer be exempt from negative vote recommendations from ISS. ISS will continue to evaluate adoptions of short-term pills (duration of 1 year or less) on a case-by-case basis, however, ISS will pay closer attention to the "rationale for their adoption" than on the company's track record and corporate governance. Consistent with ISS' current policy, renewals or extensions of existing pills will not be assessed on a case-by-case basis. Shareholder Proposals ISS adopted a new policy with regards to shareholder proposals related to gender pay gaps.